MSB 0.36% $1.39 mesoblast limited

Cell Therapy News/Articles, page-16360

  1. 1,485 Posts.
    lightbulb Created with Sketch. 3293
    Hi @Wilba32

    if I could just point out to all our regular viewers out there that this promotional material - from the Cell Therapy for Autoimmune Disease Summit - about Remestemcel-l's commercialisation challenge is written in the past tense viz: "(Conf., Day 2: Thur. Nov. 30)....how have we overcome key regulatory challenges?.".

    So what, you might say, somewhat disingenuously.

    Well, I'd (wittily?) reply, that would seem to indicate that the subject-matter is also in the past tense... it's passed on! This challenge is no more! It has ceased to be! 'It's expired and gone to meet it's maker! It's a stiff! Bereft of life, it rests in peace! Its metabolic processes are now 'istory! It's off the twig! 'It's kicked the bucket, It's shuffled off its mortal coil, run down the curtain and joined the bleedin' choir invisible!! THIS IS AN EX-CHALLENGE.

    And given that it is being published now...

    That means...

    Yep. She's a witch.

    Cheers
    Last edited by Phaedrus: 13/07/23
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.